MACROGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.60 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.47, a 34.08% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $2.23, a 84.26% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $14.17, a 275.86% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.77, a 49.60% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.81, a 85.65% decline from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $12.61, a 229.24% increase from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.83, a 44.01% decline from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.84, a 55.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $1.47 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.81 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $1.85 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.03 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $2.23 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $12.61 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $12.79 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $12.99 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $14.17 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $3.83 10-K · filed 2026-03-09 | |||
| 2023-09-30 | $3.78 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $3.78 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $3.77 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $6.84 10-K · filed 2025-03-20 | |||
| 2022-09-30 | $6.89 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $6.96 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $7.48 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $15.20 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $15.21 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $15.11 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $14.23 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $10.68 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $10.50 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $8.30 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | $7.12 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $13.98 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $14.33 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $14.38 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $14.65 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $17.90 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $18.07 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $18.29 10-Q · filed 2019-07-31 | $18.29 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $18.75 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $12.53 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $12.56 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $12.73 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $12.76 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $15.17 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $14.81 10-Q · filed 2016-11-02 | |||
| 2016-06-30 | $12.78 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $12.82 10-Q · filed 2016-05-04 | |||
| 2015-12-31 | $20.90 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $21.95 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | $21.47 10-Q · filed 2015-08-05 | |||
| 2015-03-31 | $19.05 10-Q · filed 2015-05-06 | |||
| 2014-12-31 | $17.41 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $14.75 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $14.94 10-Q · filed 2014-08-05 | |||
| 2014-03-31 | $23.13 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | $6.91 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $0.94 10-K · filed 2015-03-03 | |||
| 2011-12-31 | $0.94 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |